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The present review does not aim to describe the biological role of 
neuroinflammation within the disease process, but rather to consider 
whether inflammatory markers may have a potential use as a means of 
identifying persons with clinically silent AD for clinical intervention 
studies. Epidemiological, animal, clinical and imaging studies have 
been selected which have included data on the earliest stages of AD 
pathogenesis, as well as studies of normal persons at high AD risk. We 
examine changes in markers across time from the pre-clinical to the 
prodromal phases and also attempt to evaluate their utility alongside 
already established biomarkers. Finally, we make suggestions for future 
research design. 
Epidemiological Studies
Due to the relatively recent advent of research in preclinical AD, 
there is little epidemiological evidence linking neuroinflammation to this 
specific AD population. However, associations of several inflammatory-
related diseases, such as obesity, type 2 diabetes, rheumatoid arthritis 
and psoriasis [17-20] in the decades before AD dementia diagnosis have 
been consistently observed. Traumatic brain injury, with associated 
inflammation, has also been observed to significantly increase risk of 
AD dementia later in life [21]. Conversely, the use of non-steroidal anti-
inflammatory drugs (NSAIDs) in mid-life has been associated with a 
reduced risk of developing AD dementia in some studies [22,23] but not 
others [24,25]. Episodes of acute systemic infections, accompanied by 
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Introduction 
Increasing evidence suggests sporadic Alzheimer’s disease to be 
a clinically silent disease of mid-life, which remains undetected for 
decades until its terminal stage, characterized by dementia [1-4]. In 
light of multiple failures to develop an effective treatment for prodromal 
or clinical (dementia) AD, research efforts are now focusing on earlier 
stages of the disease process and clinical services are moving towards 
a similar model [5]. The development of therapeutic intervention 
strategies targeting the pre-clinical stages of the disorder currently 
relies, however, on our ability to identify biomarkers, which may be used 
to monitor change at this early stage. Within this context the focus is 
currently on neurological markers, notably neurodegeneration, amyloid 
and tau accumulation and pre-clinical cognitive markers [6,7]. Immune 
system changes on the other hand, although extensively studied in 
relation to prodromal AD and AD dementia, have to date been relatively 
neglected. 
While considerable attention was given to early evidence of 
neuroinflammation in AD dementia, it fell out of favour as the amyloid 
cascade hypothesis [8] became the predominant aetiological model. In 
the last decade there has been a resurgence of interest in the potential role 
that neuroinflammation may play not only as pathological consequence 
of Aβ pathology, but also as a potential trigger and accelerator of 
amyloid plaque formation and tau-related neuronal injury [9-11]. 
Inflammatory reactions have been implicated in the pathogenesis of AD 
dementia in the form of glial cells, such as astrocytes and microglia, as 
well as inflammatory components, such as cytokines and chemokines 
[11,12]. Additional support comes from associations of AD dementia 
with genes implicated in immune responses, such as TREM2, CR1 
and CD33 and chronic psychological stress [13-15]. An inflammatory 
contribution to disease pathogenies has also been observed in the 
prodromal stages of AD [16]. Given accumulating biological evidence 
that neuroinflammation may precede both Aβ and tau formation [11], it 
is of considerable interest as a potential pre-clinical marker. 
Neuroinflammation in Preclinical Alzheimer’s Disease: A Review of 
Current Evidence
Tamlyn J Watermeyer1*, Vanessa Raymont1,2 and Karen Ritchie1,3
1Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK
2Department of Psychiatry, University of Oxford, Oxford, UK 
3Faculty of Medicine, University of Montpellier, Montpellier, France
 Abstract
The pathology of sporadic Alzheimer’s disease (AD) may be present at mid-life and precede the prodromal 
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raised levels of cytokine TNF-α, have been found to correspond to an 
acceleration of cognitive decline in AD dementia patients [26], but the 
nature of inflammation’s impact in the pre-clinical period has not been 
specifically examined within epidemiological studies. 
A retrospective general population study of persons diagnosed with 
AD dementia observed that C-reactive Protein (CRP) levels were not 
significantly different ten years previously in individuals remaining 
cognitively healthy (i.e., controls) and those evolving towards AD 
dementia [4]. However, against expectation, levels of CRP in the AD 
dementia cases showed a significant downward slope closer to the 
time of diagnosis, while the control group showed a slightly raised 
curve towards the same time-point similar to the sigmoidal trajectories 
observed by Jack et al in relation to other biomarkers, notably amyloid 
and tau [27-29]. The study was limited by its restriction to a single 
inflammatory marker assessed at only one point in time and also 
limited by the older age of the population (over 65 at recruitment). The 
value of future epidemiological studies of inflammatory markers in the 
pre-clinical period will very much depend on their ability to examine 
a wider range of markers across time from mid-life, when exposure to 
many of the principal inflammation-related disorders also implicated in 
AD risk (notably obesity, diabetes and stroke) are currently postulated 
to have their principal impact. 
Animal Studies 
The occurrence of plaque-dependent inflammation has been 
robustly observed in animal models of AD [9,30], with microglia 
present in neutritic plaques [31,32] that are spatially related to dendritic 
spine loss [33]. Furthermore there is some evidence to suggest that a 
pro-inflammatory process may be initiated before plaque deposition. 
In transgenic mice overexpressing amyloid precursor protein, a 
microglial activation processes involving Il-1β and Il-6 was detected 
early at 3 months of age when amyloid plaques were not yet present 
[34]. Similarly, using a triple transgenic mice model (3xTg), Janelsins 
et al. [35] observed increased expressions of TNF-α and monocyte 
chemoattractant protein-1 (MCP-1) in the entorhinal cortex of 
three-month-old mice which coincided with the production and 
accumulation of intracellular amyloid but preceded extracellular plaque 
deposition, the latter of which occurred only at 12 months of age [35]. 
Another study found that exposure of a viral mimic (polyriboinosinic-
polyribocytidilic acid) to wild-type and transgenic mice prenatally and 
again in adulthood corresponded to an emergence of AD-like pathology 
(amyloid and tau aggregates), microglia activation and reactive gliosis 
over the course of animal ageing [36]. 
Taken together, these studies suggest that pro-inflammatory 
processes may act as very early indicators of preclinical disease. 
However, their relevance to pre-clinical AD is limited by the 
difficulties inherent in defining ‘pre-clinical’ in animal models. 
This can only currently be estimated by reference to progression of 
amyloid and tau deposition. Although human and rodent amyloid 
plaques share morphological similarities, they are distinct in 
biochemical composition [37] and might interact differently with 
other pathological features, such as inflammatory agents. Moreover, 
animal models typically involve the manipulation of genetic markers 
associated with familial forms of AD and such models might not 
correspond to the relatively more prevalent sporadic form associated 
with humans. Therefore, while animal studies provide limited evidence 
of inflammation as an upstream marker of disease, prospective studies 
are required to monitor changes before and during the evolution of 
neurological changes within the human brain. 
Clinical and Imaging Studies 
Research on the role of brain inflammation in the evolution of 
the AD began in the mid-1980s [38]. Subsequently, the inflammatory 
profiles of prodromal AD and AD dementia are relatively well described 
but present a heterogenous picture; possibly as a result of discrepant 
methodological practices and patient characterisation between 
studies [39]. Inflammation has primarily been studied in the context 
of advanced AD pathology involving amyloid plaques. Therefore, 
the involvement of elevated inflammatory agents in evolution from 
prodromal changes to dementia remains unclear, with inconsistent 
evidence for a specific risk for AD dementia [40]. Relatively few studies 
have assessed inflammatory profiles in preclinical AD, so it is even less 
clear if or how neuroinflammation promotes AD-related cognitive and 
brain changes in the direction of prodromal and clinical AD. In addition, 
the initiation of the acute inflammatory response is counterbalanced by 
an active resolution and specialized pro-resolving mediators (SPMs) 
have been identified that drive resolution by diminishing inflammatory 
molecules, such as cytokines [41]. Thus it has been suggested that age-
related deficits in resolution of inflammatory responses may contribute 
to the development of late onset AD dementia [42], including in humans 
[43]. Finally, while, preclinical evidence suggests that inflammation can 
induce tau hyperphosphorylation, a better understanding of whether 
this increases neurofibrillary tangles is needed [44].
Given that the preclinical phase of AD is, by definition, not 
observable in terms of everyday functioning, research participants 
with preclinical AD are likely to be included in studies of “healthy” or 
“normal” cohorts. Elevated levels of pro-inflammatory cytokines and 
markers, such as IL-1β, IL-6, TNF-α and CRP have been observed in 
some but not all persons over time and attributed to age [45]. It is, 
however, possible that such persons are manifesting pre-clinical AD, 
a proposition supported by studies of midlife and older normal adults 
showing elevated levels of inflammatory markers in association with 
cognitive deficits and brain changes (Table 1). 
In healthy adults, elevated YKL-40 concentrations have been 
associated with poorer Mini-Mental State Exam (MMSE) performance 
[46,47] and PAI-1 has been negatively correlated with motor speed and 
coordination [48]. Serum CRP levels have been negatively associated 
with performance on executive function tasks [49], while composites of 
CRP with other inflammatory markers have correlated with visuospatial 
function (CRP+TNF-α [50]; CRP+IL-6 [51]), verbal proficiency and 
short-term memory (CRP+IL-6 [51]). Midlife inflammation levels 
may contribute to later-life cognitive performance, as one study found 
that inflammation composite scores created from immunoassays 
ascertained at mid-life (45-65 years old) were associated with reduced 
episodic performance 24 years later [52]. 
These relationships between raised inflammatory levels and 
cognitive scores are not always demonstrated [53,54], possibly due to 
heterogeneous cognitive ability within “healthy” aged samples. For 
example, in one study, participants’ levels of inflammatory markers 
were classified into tertiles of high, middle and low values. Cognitive 
scores were adjusted for age, education-level and gender. At baseline, 
the highest tertiles of ACT and lowest tertiles of albumin were 
associated with delayed memory recall and MMSE performances, 
respectively. However, excluding participants with MMSE scores<21 
at baseline, revealed a further linear relationship between ACT and 
information processing speed, while the association between MMSE 
performance and albumin disappeared. At follow-up both ACT and 
albumin tertiles were associated with decline in MMSE performance. 
Only the association between ACT and MMSE performance remained 
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when participants with MMSE<21 at baseline were excluded from the 
longitudinal analyses [54]. These findings imply the possible sensitivity 
of different inflammatory markers to cognitive impairment at different 
stages along dementia continuums and underscore the importance of 
sub-group analyses in cognitively heterogeneous samples. 
Where these relationships between cognitive performance 
and inflammation are present, they may be partially mediated by 
inflammation’s influence on brain morphology [50,51]. Smaller 
hippocampal volumes have been found for individuals with higher 
levels of STNFR-1, STNFR-2; IL-6 and CRP [51,55,56]; these effects 
being strongest for individuals between 60-70 years [55]. In both middle 
and older healthy aged adults, higher CRP has been related to reduced 
global and regional fractional anisotropy in the frontal and temporal 
lobes, the cortico-subcortical tracts, and corpus callosum [48,49]. 
Higher IL-6 has been associated with smaller total brain volume, total 
and regional grey and white matter volumes as well as with reduced 
cortical thickness of the inferior occipital and temporal gyri [56-58]. 
The influence of prolonged inflammation on brain morphology is not 
yet clear, with one recent study finding that the presence of baseline 
inflammatory biomarkers did not modify the change of brain measures 
over time [59], but earlier reports indicating greater cortical thinning 
and white matter volume reduction at follow-up [56,57]. Age and race 
may mediate the relationship between inflammation and later-life 
brain integrity as younger and white participants with higher levels 
of systemic inflammation during midlife were more likely to show 
reduced brain volumes 24 years later [52]. 
Some studies of inflammation in healthy adult samples incorporate 
the assessment of established AD risk factors alongside immunoassay 
analyses but few studies have compared inflammatory mediators across 
the stages of preclinical dementia as defined by accepted research 
criteria [6]. These criteria propose a spectrum of stages pertaining 
to biomarker load within preclinical AD: stage 1 individuals show 
evidence of amyloid deposition only; stage 2 individuals possess both 
amyloid and neurodegeneration; while stage 3 individuals show subtle 
cognitive symptoms in addition to these biomarkers. In one study of 
cognitively normal individuals [60], those participants qualifying 
for stages 2 and 3 as well as those with suspected non-Alzheimer’s 
pathophysiology (SNAP) showed higher levels of CSF YKL-40 than 
those in stages 1 and those without amyloid evidence. At the cohort 
level, YKL-40 concentrations correlated with t-tau and p-tau deposition, 
in keeping with other research [46,61,62]. This correlation remained 
significant when amyloid positive and amyloid negative participants 
were analysed separately, emphasising a possible role for YKL-40 in 
tau hyperphosphorylation and neuronal injury, which may be at least 
partially independent from amyloid plaque deposition. The overlap 
of elevated YKL-40 levels across preclinical and SNAP participants 
further suggests that neuroinflammation may emerge independent 
of amyloidios. More recently, an assessment with a broader range of 
inflammatory markers again found no correlation of any markers 
with AB41-42 levels. Instead, six CSF markers (IL-15, MCP-1, sFLT-
1, siCAM-1 and sVCAM-1) were associated with tau pathology 
independent of age, gender, cognitive status and APOE-E4 status [63]. 
Alternatively, certain inflammatory agents may interact with amyloid 
and tau pathologies to alter brain structure in preclinical AD. In a cohort 
of mid and later life adults at risk for AD, higher MCP-1 in combination 
with lower CSF AB42 levels was associated with measures of neuronal 
injury in the bilateral frontal cortex and lateral temporal lobe, while 
higher MCP-1 in combination with higher CSF p-tau was related to 
altered microstructure in the precuneus. Elevated YKL-40 was directly 
associated with CSF levels of neurofilament light chain protein and 
t-tau, markers of neuronal injury [62]. Similarly, YKL-40 was associated 
with a change in global cognition over the course of two years in older 
adults, but only for those who were positive for amyloid pathology [64]. 
Previously, YKL40 had been associated with reduced cortical thickness 
in the middle and inferior temporal areas in a cross-sectional research, 
but this association was again only observed in participants with low 
CSF Aß42 [65]. In both studies, CSF YKL-40 and AB42 levels did not 
correlate in the positive AB42 group, suggesting that amyloid build-up 
and neuroinflammation may underlie distinct processes but may have 
additive effects on cognition and brain structure. 
Inflammatory indicators may have diagnostic and prognostic value 
in preclinical AD. Cognitively normal participants with high ratios 
Marker Main Findings 
YKL-40
Levels are significantly increased in preclinical and prodromal AD groups [46]. Levels are higher in preclinical stages 2-3 and SNAP stage compared to 
Stage 0, 1 [60]. Levels significantly correlate with t-tau and p-tau levels in preclinical AD [46], middle and older adults [62]. Levels correlated with MMSE 
and MAT performance for combined preclinical and prodromal AD groups [46] as well as change scores for global cognition in older adults [64].  
Levels correlates with cortical thinning in middle and inferior temporal areas but only in individuals with low CSF Aß42 [65]. 
CRP
An association with cognitive performance is not always demonstrated [53, 54]. Nonetheless, higher levels are associated with worse performance in 
executive function [49], while individuals within the highest tertiles of CRP show significantly lower MMSE scores overtime [47]. 
CRP levels inversely related to white matter integrity in corticosubcortical pathways and association fibres of frontal and temporal lobes [48]; global and 
regional FA scores of the frontal lobes, the corona radiata and the corpus callosum [49] as well as regional gray matter volume in the posterior and lateral 
aspects of left temporal cortex [58].
PAI-1 Levels correlate with lower processing speed and motor coordination [48]. Higher levels associated with white matter integrity loss in corticosubcortical pathways and association fibres of frontal and temporal lobes [48]. 
ACT Highest tertile of ACT was associated with lower delayed recall scores cross-sectionally and greater decline on MMSE longitudinally [54]. 
IL-6
As part of a composite with CRP, has been negatively associated with tests of spatial processing, short-term memory, verbal proficiency, verbal learning 
and memory, executive function [51] as well as episodic performance [52].
Higher levels associated with reduced cortical thickness in inferior occipital gyrus and sulcus, inferior temporal gyrus (both hemispheres) crossectionally. 
Higher levels associated with cortical thinning in: frontopolar gyri and sulci; right subcentral gyrus and sulci; inferior temporal poles (bilatreal) and left 
occipital pole and right calcarine sulcus cortex overtime [57].
TNF-a As part of composite with CRP, has been associated with correlated with visual spatial ability. DA in the body and isthmus of the corpus callosum was shown to mediate this association [50]. 
Composites
Composite (fibrinogen, albumin, white blood cell count, von Willebrand factor, Factor VIII,) was negatively associated with episodic memory and was 
associated with greater ventricular degeneration, smaller hippocampal and occipital volumes [52]. 
Composite (cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF, GRO-a, fibrinogen, FAS, eotaxin-3) significantly enhanced the ability of 
tau/Ab42 ratio, to discriminate CDR 0 from CDR 0.5 [67]. 
CSF: Cerebral Spinal Fluid; MMSE: Mini-Mental Status Exam; MAT: Memory Alteration Test; FA: Fractional Anisotropy; DA: Diffusion Anisotropy
Table 1: Summary of clinical and imaging studies for healthy participants and preclinical AD.
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of CSF YKL-40/Aβ42 have been found to progress faster to cognitive 
impairment compared to those with lower ratios [61]. A combination 
of markers (Table 1, Composites) was shown to enhance the ability 
of the tau/Aβ42 ratio to discriminate mild AD, prodromal AD and 
cognitively healthy individuals, as defined by the Clinical Dementia 
Rating scale [66,67]. More recently, the inclusion of certain of certain 
serum (cFGF, CRP, IL-16, sFLT-1, sICAM-1, Tie-2, VEGF-C and 
VEF-D) and CSF (IL-15, MCP-1 and sFLT-1) inflammatory markers 
significantly improved the accuracy of classification for AD pathology 
in cross-sectional samples of healthy older adults, prodromal AD and 
mild AD dementia patients [63].
Discussion and Conclusion
The evidence considered in this review largely suggests that 
inflammation is present in preclinical AD and is associated with AD 
pathogenesis. Some findings from animal and clinical studies propose 
that inflammatory processes might precede or be independent from 
amyloid deposition, suggesting that these markers constitute the 
earliest indicators of preclinical disease. Some studies demonstrate 
direct associations with tau pathology, cognitive performance and 
brain changes; others identified interaction effects, where the presence 
of inflammation in combination with amyloid and/or tau pathology 
influenced neurodegeneration. 
It is unclear whether inflammatory markers are associated with 
particular clinico-pathological characteristics that may underlie 
heterogeneous outcomes within aging and preclinical cohorts; for 
example, individuals who subsequently develop prodromal and 
clinical dementia compared to those who do not. Nonetheless, there 
is some evidence that inflammatory markers may possess diagnostic 
or prognostic value for future AD symptomology. Additional studies 
focusing on impaired resolution of inflammation, especially on 
tau related neurofibrillary pathology are needed, as are studies that 
examine whether such responses are dose-dependent and relevant to 
AD in humans. 
Large epidemiological studies of preclinical AD are notably absent. 
The use of animal models, while undoubtedly facilitate knowledge of 
the various molecular mechanisms of AD, may not be the optional 
paradigms to simulate the preclinical stages of the disease. While it 
appears that elevated levels of inflammation are associated with cognitive 
processing deficits and morphometric changes in “healthy” adults, there 
is a distinct lack of preclinical AD samples available to investigate similar 
relationships in these individuals. The range of inflammatory markers 
investigated in preclinical AD studies is narrow and it is not yet possible 
to infer which agents, acting alone or in combination, are relevant in 
the proposed inflammatory process, and if they may support or prevent 
AD development at different stages of disease. The majority of these 
studies are cross-sectional, limiting inferences regarding causality, and 
temporal relationships between inflammation, cognitive performance 
and neurodegeneration. Where longitudinal designs have been adopted, 
few studies have captured inflammatory measures serially, using only 
baseline data to predict future cognitive and brain changes at follow-
up. Single clinical assessments may over- or under-estimate the level 
of inflammation chronicity for the individual at baseline and precludes 
investigations of the impact of changes in inflammation markers, or 
combinations thereof, on neurodegenerative and cognitive outcomes. 
Further clinical and imaging studies with longitudinal data and the 
ascertainment of inflammatory agents alongside neuropathological 
and cognitive markers earlier in the disease course and at predefined 
times throughout disease duration is needed to the determine the 
contribution of inflammation within the cascade of pathological and 
cognitive changes associated with AD.
Interest in inflammation and AD is building and there are 
numerous benefits of developing this area of research within preclinical 
AD. Delineating the role and timing of neuroinflammation in this 
population will help to reconcile conceptual debates surrounding 
AD aetiology. Relatedly, including inflammatory markers alongside 
established biomarkers in future research studies could improve 
diagnostic accuracy of participant samples and help stratify individuals 
according to greatest risk for cognitive impairment, leading to smaller 
and more cost-effective observational and clinical trials that promote 
earlier disease detection and targeted therapeutic intervention. At 
present, the immediate clinical application of these markers for 
diagnostic purposes remains elusive since research studies are only 
beginning to consider their use for extending current definitions of 
preclinical AD. Future work will be able to assess the impact of utilising 
inflammatory markers on diagnostic decision-making and patient 
management in clinical contexts. 
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